Clinical News

UEG is calling on all EU countries to evaluate advanced CRC screening techniques to help increase survival rates

Tuesday, 17 March 2015 10:14

The Colorectal Cancer Awareness month kicks off UEG's latest campaign "Screening Saves Lives (CRC) 2015". Colorectal cancer accounts for about half of all gastrointestinal malignancies in Europe and the annual incidence is predicted to rise by 12% by 2020. UEG is calling on everyone over 50 to 'Step Up, Take the Test'. Read full press release and follow this campaign on Twitter #ScreeningSavesLives.

Recruitment to the Quality Standard Advisory Committee for Irritable Bowel Syndrome

Wednesday, 11 March 2015 09:49

Recruitment for specialist membership of the NICE Irritable Bowel Syndrome Quality Standard Advisory Committee (QSAC) is now open and applications are being sought for the following roles:

  • Gastroenterologist
  • GP
  • Lay member

Information on the posts is available on the NICE website, please follow these links for details:

The deadline for applications is 7th April at 17.00.

Nice Quality Standards for IBD

Friday, 27 February 2015 10:42

Professor Chris Probert, Chair BSG IBD Section Committee

"The BSG welcomes the release of Quality Standards for IBD by NICE. The four statements are necessarily succinct and members should read the more detailed version on the NICE website. This document sets a standard that should be recognised by CCGs and Trusts and should enable us to raise the quality of our services. These standards should form the basis of the forthcoming IBD Accreditation, along with the IBD Audit and Registry."

Changes in HCV therapy - approval of Sofosbuvir

Friday, 30 January 2015 13:55

Dr Stephen Ryder, BSG Vice-President Hepatology & Dr Andrew Austin, Chair BSG Liver Section

There are two major changes in HCV therapy which now have NICE and/or NHSE approval for use. The first is that commissioning guidance for the use of Simiprevir is published (http://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-a/a02/). This allows G1 patients without Q80K to access triple therapy now using Simiprevir instead of Boceprevir or Telaprevir.

The second and probably more significant development is the approval of Sofosbuvir. The approval can be summarised as below:

 

Sofosbuvir in combination with pegylated interferon + ribavirin (Peg-IFN+RBV)

HCV genotype Adult patient population
Genotype 1 Treatment-naïvea
  Treatment-experienceda
Genotype 3 Treatment-naïve with cirrhosisa
  Treatment-experienceda
Genotype 4, 5, or 6 Treatment-naïve & experienced with cirrhosisa

 

Sofosbuvir in combination with RBV

HCV genotype Adult patient population
Genotype 2 Treatment-naïveb
Treatment-experienceda
Genotype 3 Treatment-naïve with cirrhosisb
Treatment-experienced with cirrhosisb

The NHSE approval is for cirrhotic patients to access treatment in April with non-cirrhotic patients from July.

There is a meeting at Barts on 3rd March 2015 (advertised by BVHG) to establish clinical guidelines as to who to treat with what when. It is highly likely that by July other agents approvals will make the interferon component of the regimen outdated. NHSE will establish a process by which the drugs will be distributed shortly but it would seem prudent for centres to enter local negotiations now in order all are ready to prescribe when we are given the approvals. It is pretty certain that similar data gathering will be required as for EAP.

Page 1 of 3